UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl)
UvA-DARE (Digital Academic Repository)
Human herpesvirus 8 and Kaposi's sarcoma in the Amsterdam cohort studies.
Disease association, transmission and natural history
Renwick, N.M.
Publication date
2001
Link to publication
Citation for published version (APA):
Renwick, N. M. (2001). Human herpesvirus 8 and Kaposi's sarcoma in the Amsterdam cohort
studies. Disease association, transmission and natural history.
General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s)
and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open
content license (like Creative Commons).
Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please
let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material
inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter
to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You
will be contacted as soon as possible.
ddendum m
Timingg of Human Immunodeficiency Virus type 1
andd Human Herpesvirus 8 Infections and length of the
Kaposi'ss sarcoma-free period in coinfected persons
NeilNeil Renwiek, Gerritjan Weverling, Thomas Schulp and Jaap Goudsmit
T oo the Editor
Inn 1998, we reported that human immunodeficiency virus typee 1 (HIVT)-infected homosexual men have the highest riskk of developing Kaposi's sarcoma (KS) if they acquire humann herpesvirus 8 (HHV-8) after HIV infection (1). This observationn has been confirmed recently by jacobson e t al. (2),, who also found that the duration of HIV-1 infection be-foree HHV-8 acquisition influences the risk for KS. There-fore,, we (1) and Jacobson et al. (2) suggested that immuno-deficiencyy at the time of primary HHV 8 infection may shortenn the KS-free period.
Inn a subsequent correspondence, Rezza (3) suggested that thiss is not necessarily the case, since most cases of trans-plantt associated KS in an HHV-8-endemic country oc-curredd in patients who had acquired HHV 8 before trans-plantationn (4). Rezza infers from these data that factors like HIV-11 Tat and/or inflammatory cytokines, rather than immunosuppression,, might be responsible for the in-creasedd incidence of KS in HIV-1 and HHV-8 coinfected persons. .
[acobsonn and Jenkins (5) responded to the report by Rezza (3)) by suggesting that KS in HIV 1-negative transplant re-cipientss cannot be formally compared with KS in HIV 1-positivee individuals in regard to the impact of
immunosuppressionn on the rate of progression of HHV 8 infectionn to KS. We agree with the comments of Jacobson andjenkinss and wish to point out that, in oir original report (1),, CD4 cell count, not HIV-1 virus load, was an independ-entt risk factor for KS. In our view, it is therefore more likely thatt HIV related immunodeficiency, rather than steadv-statcc levels of HIV in blood, and, bv inference, levels of HIV-11 Tat or inflammatory cytokines increase the risk for KS. .
References s
11 Renvick N , I lalabv T, Weverling ( i | , </<//. Seroconversion for hu-mann herpesvirus 8 is highly predictive of Kaposi's sarcoma. .-UD\ 1998;12:2481-8. .
22 Jacobson 1.1', Jenkins FJ, Springer (I, et al. Interaction of human immunodeficienevv virus type 1 and human herpesvirus type 8 in-fectionss on the incidence or Kaposi's sarcoma. / Infect Pis 2000;181:1940-9. .
33 Re/za (). Immunosuppression, timing of human herpesvirus 8 in tection,, and risk of Kaposi's sarcoma among human immunodefi-ciencyy virus rvpc 1-infected persons and transplant recipients. / 7«/rt7/)/.r2lMM);|| 82:1809.
44 Parravacini C, ()lsen SI, Capra M, ft al. Risk of Kaposi's sar-coma-associatedd herpes virus transmission from donor allograft amongg Italian posttransplant Kaposi's sarcoma patients. /WW
]] 997.91 ):2H21-9.
55 Jacobson LP, Jenkins FJ. Reply. / Infect Dis 2000; 182:1809-ld.
